Quick Links

jewish general hospital

No increased heart failure with incretin-based drugs

McGill Newsroom

Canadian drug safety network provides reassuring evidence regarding risk of heart failure of anti-diabetes medications

Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study published in the New England Journal of Medicine.

Published: 24Mar2016

Diabetes drug found not to cause pancreatic cancer

By Tod Hoffman, Lady Davis Institute for Medical Research

The use of incretin-based drugs is not associated with an increased risk of pancreatic cancer in patients with type 2 diabetes, according to a study published in the latest issue of the British Medical Journal (BMJ).

The research was conducted by the Canadian Network for Observational Drug Effect Studies (CNODES), which used the health records of almost 1 million patients with types 2 diabetes.

Published: 22Feb2016

Treatment for dry eye disease based on McGill research

The discovery that tavilermide  induces the production of mucin, a crucial lubricant in tears, offers hope of relief to people who suffer from chronic dry eye disease. The invention and the development of a drug based on this small molecule was made by the team of Dr. H. Uri Saragovi, Senior Investigator at the Lady Davis Institute (LDI) at the Jewish General Hospital and Professor of Pharmacology at McGill University.

Published: 3Dec2015

Clinical Trial for Type 1 Diabetes Begins at JGH, MUHC

Landmark Clinical Trial of a Novel Combination Treatment for Type 1 Diabetes Begins at Jewish General Hospital and McGill University Health Centre

Published: 25Nov2015

Family Medicine to the Rescue Throughout the Life Cycle

22May201312:00
to
12Jun201312:00
Jewish General Hospital 3755 Cote St. Catherine Road, Montreal, QC, H3T 1E2, CA

Wednesday evenings, May 22 - June 12, 2013
Presentations in English.